Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22370614 | 1.00 | MEN1 (0.55) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL16389072 | 0.94 | KMT2A (0.56) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL12989831 | 0.92 | MEN1 (0.64) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL30340151 | 0.89 | MEN1 (0.51) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL22370726 | 0.89 | TDP1 (0.48) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL22388208 | 0.89 | TDP1 (0.48) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL21906253 | 0.88 | MEN1 (0.50) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL17841802 | 0.86 | MEN1 (0.48) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL16424876 | 0.86 | MEN1 (0.56) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL13702219 | 0.86 | MEN1 (0.58) | MEN1KMT2AGAATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12312370-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-111491938-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3710458-A1 | IMMUNOPROTEASOME INHIBITORS | Principia Biopharma Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
| CN-111491938-A | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2020-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | MEN1 3171/4885KMT2A 1002/4885GAA 164/4885 |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | MEN1 3171/4885KMT2A 1002/4885GAA 164/4885 |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | MEN1 3171/4885KMT2A 1002/4885GAA 164/4885 |
| US-12312370-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | MEN1 3171/4885KMT2A 1002/4885GAA 164/4885 |
| US-11225493-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | MEN1 3171/4885KMT2A 1002/4885GAA 164/4885 |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | MEN1 3171/4885KMT2A 1002/4885GAA 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.